Abstract-The cardioprotective mechanisms of colchicine in patients with stable ischemic heart disease remain uncertain. We tested varying concentrations of colchicine on platelet activity in vitro and a clinically relevant 1.8-mg oral loading dose administered over 1 h in 10 healthy subjects. Data are shown as median [interquartile range]. Colchicine addition in vitro decreased light transmission platelet aggregation only at supratherapeutic concentrations but decreased monocyte-(MPA) and neutrophil-platelet aggregation (NPA) at therapeutic concentrations. Administration of 1.8 mg colchicine to healthy subjects had no significant effect on light transmission platelet aggregation but decreased the extent of MPA (28 % 
INTRODUCTION
Colchicine is an anti-inflammatory agent commonly used in rheumatic diseases and pericarditis [1] . Recent data suggest potential benefit in other systemic inflammatory disease processes, including atherosclerotic heart disease [2, 3] . The cardioprotective mechanisms of colchicine have not been fully elucidated. Microtubules support the discoid shape of platelets and may play a role in platelet activation [4] [5] [6] [7] [8] . Colchicine disrupts microtubule polymerization and dissociation and thus may inhibit platelet activation. The effect of colchicine on platelet activity is currently limited to in vitro studies or examination of platelet aggregation in clinical models [4] [5] [6] [7] [8] . The aim of the current study was to evaluate the effects of colchicine both in vitro and in vivo in healthy human subjects, with particular regard to homotypic versus platelet-leukocyte interactions.
METHODS

In Vitro Experiments
Phlebotomy was performed in healthy subjects above the age of 21 years and not on any medications. After a 2 cc discard, blood was collected in 3.2 % (0.109 mol/L) sodium citrate tubes (BD Vacutainer, 2.7 mL). Good clinical practice protocols were followed to certify proper storage and daily and long-term quality control of reagents, instruments, and technique. Colchicine powder was obtained from Sigma Chemical Co. (St. Louis, MO) and diluted in PBS. Concentrations of colchicine used for the experiments described below were based on peak blood concentration (6 ng/mL or 0.015 μM) after ingestion of 1.8 mg PO load of colchicine over 1 h [9] .
Platelet aggregation was measured via light transmission aggregometry (LTA) using the AggRAM light transmission aggregometer (Helena Biosciences, Beaumont, TX). Briefly, citrate-anticoagulated blood was centrifuged at 200g for 10 min to obtain platelet-rich plasma (PRP) [10] . For these experiments, PRP was incubated with varying concentrations of colchicine (0, 0.015, 0.15, 1.5, 15, 150, 1500, 15000 μM) for 30 min at room temperature. LTA was immediately performed, and platelet aggregation was assessed in response to submaximal adenosine disphosphate (ADP) and epinephrine concentrations (1 and 0.4 μM, respectively) and recorded at maximum aggregation over a 10-min evaluation.
Since an initial step of platelet activation is the adherence of platelets to leukocytes, the extent of monocyte-(MPA) and neutrophil-platelet aggregation (NPA) was investigated [11] . Citrate-anticoagulated blood was incubated with varying concentrations of colchicine (0, 0.015, 0.15 μM) at room temperature, followed by 0.05 U thrombin. The mixture was then stained with CD61-FITC (platelets) and CD14-APC (monocytes), and samples were evaluated immediately on an Accuri C6 flow cytometer (BD Biosciences, Franklin Lakes, NJ). MPA was assessed using CD14 to identify the monocyte population, and NPA was assessed using forward/side light scattering characteristics to identify the neutrophil population. Data are expressed as a percentage of all monocytes or neutrophils positive for adherent platelets. In these experiments, 2000 monocytes and 10,000 neutrophils per sample were analyzed [12, 13] .
Healthy Subjects Study Design
We conducted a prospective study of healthy adults with no chronic medical problems or current prescription medication use. Exclusion criteria included the following: (1) history of cardiovascular disease, (2) history of myelodysplasia, (3) use of medications (prescription or over the counter) known to affect platelet function, including non-steroidal anti-inflammatory drugs, anti-histamines, and selective serotonin reuptake inhibitors within 5 days of study procedures, (4) history of intolerance to colchicine, (5) symptoms of acute or chronic diarrhea, nausea or vomiting within 1 month of study procedures, (6) known anemia or hemoglobin <10 mg/dL, (7) platelet count <100,000 or >450,000 K/μL, (8) creatinine clearance <30 cc/min, (9) any known hemorrhagic diathesis, (10) current pregnancy, or (11) participation in a competing study. The study is registered at ClinicalTrials.gov (identifier: NCT02140372). The study was approved by the New York University School of Medicine Institutional Review Board and all subjects provided written informed consent.
Demographic information was self-reported. Height, weight, and abdominal circumference were measured by trained research nurses or assistants. Pertinent medical history was obtained from subject interview and questionnaire. Subjects fasted overnight and refrained from intensive exercise and tobacco use for 8 h prior to study procedures. Phlebotomy was performed via standard venipuncture with a 19-guage needle. After a 2-cc discard, blood was collected in 3.2 % (0.109 mol/L) sodium citrate tubes (BD Vacutainer, 2.7 mL). Colchicine tablets (0.6 mg) were obtained from the New York University Clinical Translational Science Institute investigational pharmacy. After obtaining a baseline blood sample, subjects were administered 1.2 mg colchicine by mouth followed by 0.6 mg colchicine by mouth 1 h later. Subsequent blood samples were drawn 2 and 24 h after completion of the 1.8 mg colchicine loading dose.
Measurements of Platelet Activation and Adhesion
For the evaluation of platelet activity via LTA, citrateanticoagulated blood was centrifuged within 15 min of collection at 200g for 10 min to obtain PRP. LTA was performed 30 min later on the AggRAM light transmission aggregometer. Platelet aggregation was assessed in response to submaximal ADP and epinephrine concentrations and recorded at maximum aggregation over a 10-min evaluation.
For the evaluation of platelet activity via extent of MPA and NPA, platelet surface PAC-1 expression, and platelet surface P-selectin expression, citrateanticoagulated blood was processed within 15 min of collection. Whole blood was incubated with CD61-FITC or CD42b-APC (platelets), CD14-APC (monocytes), CD45-APC (leukocytes), PAC-1-FITC, and CD62-FITC (P-selectin) antibodies and evaluated on an Accuri C6 flow cytometer. MPA was assessed using CD14 to identify the monocyte population, and NPA was assessed using CD45 and forward/side light scattering characteristics to identify the neutrophil population. Monocytes and neutrophils with adherent platelets were identified by CD61/CD42b positivity.
For the evaluation of platelet adhesion, platelets were isolated from citrate-anticoagulated blood and stained with 1 μM DiO. Following a second isolation process, stained platelets were resuspended in Tyrodes buffer at a concentration of 1×10 5 platelets/μL. Coverslips (18 mm) were coated with 100 μg/mL collagen at 37°C for 1 h, followed by addition of 0.1 U thrombin prior to addition of 1 mL isolated stained platelets. Platelets were incubated at 37°C for 30 min, and the wells were then washed twice and analyzed using an Evos FL fluorescence microscope (Thermo Fisher Scientific Inc., Waltham, MA). Platelet adhesion was quantified using ImageJ software (US National Institutes of Health, Bethesda, Maryland).
Statistical Analyses
The study was designed as a pilot evaluation, so no comparator group was studied. Continuous variables are presented as median (interquartile range), and categorical variables are presented as proportions. Markers of platelet activity before and at 2 and 24 h after colchicine administration were compared with Wilcoxon signed-rank test for continuous variables (Statistical Package for the Social Sciences, IBM, Armonk, NY). Statistical significance was inferred at a two-sided p value <0.05.
RESULTS
In Vitro Assessment
In vitro addition of colchicine to PRP significantly decreased platelet-platelet aggregation only at concentrations >1.5 μM (Fig. 1) . Similar results were noted when colchicine was added to whole blood, and with colchicine incubation times ranging from 2 to 60 min (data not shown). In contrast, in vitro addition of colchicine to whole blood decreased MPA and NPA at a concentration of 0.015 μM (Fig. 2) . Colchicinetreated platelets demonstrated viability with characteristic forward/side light scattering pattern on flow cytometry at all the examined concentrations of colchicine.
In Vivo Colchicine Administration-Prospective Healthy Subject Cohort
Baseline characteristics of the study cohort (n=10) are shown in Table 1 . The 1.8-mg oral load of colchicine had no significant effect on platelet aggregation in response to 1 μM ADP and 0.4 μM epinephrine (Fig. 3) . In contrast, colchicine administration significantly decreased the extent of MPA and NPA at 2 h but not at 24 h (Fig. 4) . Platelet surface expression of PAC-1 and P-selectin also significantly decreased 2 h after the 1.8-mg load of colchicine, an effect that was sustained for PAC-1 but not P-selectin expression at 24 h (Fig. 5) .
In subjects with available platelet/collagen adhesion data (n=8), we observed a numerical, but not statistically Continuous variables presented as median (interquartile range). Categorical variables presented as n significant, decrease in the proportion of platelets adherent to collagen after the administration of colchicine (Fig. 6) . However, when the one subject with increasing adherence over time was removed, the proportion of platelets adherent to collagen was significantly lower by 24 h after the administration of colchicine (p=0.018).
DISCUSSION
Recent data suggest that colchicine may be effective in decreasing cardiovascular events. While colchicine is used clinically as an anti-inflammatory drug, in vitro studies suggest that platelet microtubules may be an additional target of this drug. This study demonstrated that the current standard of care 1.8-mg loading dose of oral colchicine decreases platelet activity as it relates to platelet activation and the platelet-leukocyte interface but may not directly impact on platelet-platelet interactions.
Our in vitro data suggest that addition of colchicine for 30 min decreases platelet aggregation only at supratherapeutic concentrations (>0.015 μM). This finding is consistent with a study by Karpatkin et al. that demonstrated a decrease in platelet aggregation in response to Fig. 3 . Effect of a 1.8 mg load of colchicine on platelet aggregation maximal platelet aggregation was assessed before and 2 and 24 h after completion of the 1.8-mg load of colchicine in response to 1 μM adenosine disphosphate (a) and 0.4 μM epinephrine (b) over a 10-min evaluation in healthy subjects (n =10). Medians shown via dashed line. Fig. 4 . Effect of a 1.8-mg load of colchicine on platelet surface expression of PAC-1 and P-selectin extent of monocyte-platelet aggregate (a) and neutrophilplatelet aggregate (b) were assessed before and 2 and 24 h after completion of the 1.8-mg load of colchicine in healthy subjects (n = 10). Medians shown via dashed line.
ADP, epinephrine, and collagen when PRP was preincubated for 2 min with 250 to 2000 μM colchicine but not at lower concentrations [4] . Moreover, Bouaziz et al. observed a decrease in microtubular content and tubulin polymerization when thrombin-stimulated platelets were pre-incubated for a longer time period (120 min) with 10 to 1000 μM colchicine but demonstrated a modest 20 % decrease in platelet aggregation only when these platelets were treated with 100 to 1000 μM colchicine [14] . Although the current study used a 30-min colchicine incubation time, we also observed no difference between colchicine incubation times of 2 and 60 min. Since we did not use thrombin as an agonist, we cannot comment on the aggregation response to thrombin in the current study.
Mechanistic in vitro studies suggest that therapeutic concentrations of colchicine bind to platelet tubulin and modulate microtubular-associated protease, which in turn either prevents phosphoprotein synthesis or degrades existing phospoproteins required for microtubular polymerization [4, 15] . Based on our study, this putative mechanism of action may not translate into functional effects on platelet aggregation in the setting of therapeutic oral colchicine administration. One pilot study did evaluate the effect of oral colchicine 1 mg/day in 80 patients with acute coronary syndrome or acute ischemic stroke on a background of aspirin therapy, 85 % of which were on dual antiplatelet therapy with clopidogrel [16] . In a subgroup of 49 patients with platelet aggregation measured, there was no noted difference in platelet aggregation in response to ADP, arachidonic acid, or collagen [16] . Likewise, another study demonstrated no difference in mean platelet volume, a marker of platelet activity based on size, between patients with familial Mediterranean fever on colchicine and ageand sex-matched healthy subjects [13, 17] . Overall, these data suggest that colchicine may not inhibit platelet homotypic aggregation within the pharmacologically achievable range in humans.
Colchicine does, however, exert anti-inflammatory effects by decreasing neutrophil surface expression of Lselectin, suppressing neutrophil tyrosine phosphorylation and subsequent granule enzyme release, decreasing IL-1β production by the NLRP3 inflammasome, and decreasing qualitative expression of E-selectin on endothelial cells [18] [19] [20] . In the current study, we observed decreases in both MPA and NPA after in vitro addition of therapeutic concentrations of colchicine, as well as after oral administration of the standard 1.8-mg colchicine load. MPA and leukocyte platelet aggregates (LPA) are robust markers of platelet adhesion, and levels are elevated in patients with coronary artery disease, an inflammatory process, as well as associated with models of myocardial reperfusion injury [21] [22] [23] . Likewise, PAC-1, a mediator of platelet-toplatelet adhesion, and P-selectin, a mediator of plateletto-leukocyte adhesion, both decreased after oral administration of colchicine.
The decrease in adhesion to collagen observed after oral administration of colchicine was apparent at 2 and 24 h. The lack of statistical significance was likely due to the limited statistical power of our small sample size. In fact, after excluding a single outlier in our dataset, the adhesion was significantly lower following colchicine. One prior study evaluated the effects of a 60-min incubation of platelet suspensions with a supratherapeutic concentration of colchicine (10,000 μM) and noted partial inhibition of platelet adhesion to glass slides [24] . Those platelets also demonstrated partial membrane extension with short filopodia.
Our study has a number of limitations. As a mechanistic pilot study evaluating the effects of colchicine on several markers of platelet activity in 10 healthy subjects, the effect of colchicine on platelet aggregation in a larger population, as well as the clinical ramifications of the results presented herein, remains uncertain. Furthermore, representative markers of platelet activity were evaluated, but only a limited number of agonist concentrations were tested in the setting of LTA. Finally, the effects of colchicine on a background of antiplatelet therapy were not evaluated. Nonetheless, we note that prior studies by Nidorf et al. suggest that colchicine may have cardioprotective effects even among patients concurrently taking aspirin. We believe the data presented herein provide biological plausibility for larger studies examining the effects of colchicine use on platelet activity in patients with coronary artery disease on aspirin monotherapy, as well as those on dual anti-platelet therapy with aspirin and a P2Y12 inhibitor. Taken together, our data suggest the possibility that in vivo, colchicine may have a beneficial cardiovascular effect by targeting the plateletinflammatory axis. Whether targeting this pathway in vivo can offer protection from atherothrombosis without increasing the bleeding risk observed with traditional platelet-directed therapies remains unknown and deserving of future investigation.
